Story perspectives

GSK Prepares for Tariffs, Eyes £40 Billion Revenue Goal

5/2/2025

44 5

Summary

GSK Navigates Tariffs

GSK is proactively preparing for potential U.S. pharmaceutical tariffs, showcasing market resilience.
CEO Emma Walmsley outlined strategies to mitigate tariff effects, focusing on supply chain and productivity enhancements.
In Q1 2025, GSK achieved a 4% sales increase, led by specialty medicines, despite a 7% drop in vaccine sales.
The company targets over £40 billion in revenue by 2031, bolstered by new product launches.
GSK is expanding its U.S. presence with plans for a sixth manufacturing plant.

Summary

Trump Proposes Pharmaceutical Tariffs

President Trump proposed tariffs on foreign pharmaceuticals in early 2025 to enhance US production, sparking concerns over drug prices.
The EU expressed worries that the US investigation into pharmaceutical imports may harm healthcare systems through potential tariffs.
A proposed 25% tariff could raise US drug costs by $51 billion annually, leading to a 12.9% price increase for consumers.
Pharmaceutical companies are increasing investments in US manufacturing to adapt to changing trade policies.

History

Historical Context

GSK's proactive measures against potential U.S. pharmaceutical tariffs echo historical trade tensions, particularly the 1980s when the U.S. imposed tariffs on foreign goods to protect domestic industries. Similar to past responses, companies are now investing in local manufacturing to adapt. The proposed tariffs could significantly impact drug prices, reminiscent of the 2018 tariffs on steel and aluminum that raised costs across various sectors.

1 of 3

GSK Navigates Tariffs

GSK is proactively preparing for potential U.S. pharmaceutical tariffs, showcasing market resilience.
CEO Emma Walmsley outlined strategies to mitigate tariff effects, focusing on supply chain and productivity enhancements.
In Q1 2025, GSK achieved a 4% sales increase, led by specialty medicines, despite a 7% drop in vaccine sales.
The company targets over £40 billion in revenue by 2031, bolstered by new product launches.
GSK is expanding its U.S. presence with plans for a sixth manufacturing plant.

1 / 3